IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab ...

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

Researchers have used multivalent amidinium ligands to boost perovskite solar cell efficiency to 25.4%, achieving over 95% ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from ...

A new adaptive metaskin hides objects from thermal cameras in both hot and cold environments, automatically adjusting its ...

Researchers in the Republic of Korea are pushing smart-window design beyond glass. Professor Sung Ho Song at Kongju National ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Nigeria’s satellite broadband market is entering a new competitive phase after NCC granted Amazon’s Project Kuiper a 7-year ...

Callan JMB Inc. (NASDAQ: CJMB), ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

The same analysis performed on data from the similarly designed SELECT-PsA 1 trial in psoriatic arthritis showed similar ...